Previous 10 | Next 10 |
-- Currently evaluating tamibarotene in combination with azacitidine pivotal SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed HR-MDS patients with RARA gene overexpression – Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new ...
Summary Syros Pharmaceuticals is developing cancer therapies. Its most advanced potential therapy is tamibarotene for MDS. The September merger with Tyme Technologies and cash raise provides a cash runway to 2025. Syros Pharmaceuticals ( SYRS ) is a small-cap, clinical sta...
-- Expect to Complete Enrollment in SELECT-MDS-1 Phase 3 Trial in 4Q 2023; Data Expected in 3Q 2024 -- -- On Track to Initiate Randomized Portion of SELECT-AML-1 Phase 2 Trial in 1Q 2023; Initial Data Expected 4Q 2023 -- -- Entering 2023 in Strong Financial Position, with Cash i...
Combination of tamibarotene and azacitidine in a Phase 2 trial demonstrated a high complete response rate, with rapid onset and clinically meaningful durability in newly diagnosed unfit acute myeloid leukemia (AML) patients with RARA overexpression Targeting RARA overexpression with tamib...
– 83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression – - Initial safety and clinical activity profile of the triplet regimen supports advancing SELECT-AML-1 into the randomized portion– – Managem...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet ...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. Managem...
Syros Pharmaceuticals, Inc. (SYRS) Q3 2022 Earnings Conference Call November 14, 2022 08:30 AM ET Company Participants Karen Hunady - Director-Corporate Communications & Investor Relations Nancy Simonian - President & Chief Executive Officer David Roth - ...
Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q3 GAAP EPS of -$3.21 beats by $0.30 . Revenue of $3.9M (-31.6% Y/Y) misses by $1.28M . The company expects that its existing cash, cash equivalents and marketable securities of $244.5M will be sufficient to...
Closed Merger with TYME Technologies and Concurrent PIPE; Proceeds from Combined Transactions Augment Cash Balance, Ending Third Quarter with Approximately $245 Million and Extending Cash Runway into 2025 Initial Data from Safety Lead-in Portion of SELECT-AML-1 Phase 2 Trial t...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...